Basit öğe kaydını göster

dc.contributor.authorTanakol, Refik
dc.contributor.authorAlagol, Faruk
dc.contributor.authorAtas, Riza
dc.contributor.authorBoztepe, Harika
dc.contributor.authorYARMAN, Emine Sema
dc.contributor.authorSalman, Serpil
dc.date.accessioned2022-02-18T09:12:49Z
dc.date.available2022-02-18T09:12:49Z
dc.date.issued2008
dc.identifier.citationSalman S., Atas R., Tanakol R., Boztepe H., YARMAN E. S. , Alagol F., "Bowel Cleansing with Oral Sodium Phosphate is a Risk Factor for Nephropathy in Acromegaly", TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, cilt.12, sa.4, ss.104-106, 2008
dc.identifier.othervv_1032021
dc.identifier.otherav_245199fe-a3bf-4ff5-bec0-3ddf7d5c7695
dc.identifier.urihttp://hdl.handle.net/20.500.12627/176737
dc.description.abstractBecause of increased risk of colorectal carcinoma, screening by colonoscopy is recommended in patients with acromegaly. Cleansing should be vigorous in these patients due to increased bowel length and delayed colonic transit time. Recently, cases of phosphate nephropathy associated with a widely preferred purgative oral sodium phosphate (OSP) have been reported. Although main risk factors for phosphate nephropathy have been described, acromegaly has not been included as a risk factor. The present case is a 63-year old male patient, who developed transient renal failure after using three doses of OSP, which increased the serum phosphate level by 8.1 mg/dL. An acromegalic patient may have many risk factors for phosphate nephropathy after OSP administration, including having high basal serum phosphate levels, increased bowel transit time, need for high purgative dosages, increased tubular phosphate reabsorption, advanced age, and concurrent administration of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Physicians should be warned against the risks of using OSP in acromegalic patients, and intensive follow-up is necessary in the hospital setting soon after OSP administration. Therefore, we suggest that acromegaly should be included as a risk factor for nephropathy due to OSP in the current guidelines.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectEndocrinology
dc.subjectEndocrine and Autonomic Systems
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.titleBowel Cleansing with Oral Sodium Phosphate is a Risk Factor for Nephropathy in Acromegaly
dc.typeMakale
dc.relation.journalTURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
dc.contributor.departmentİstanbul Teknik Üniversitesi , ,
dc.identifier.volume12
dc.identifier.issue4
dc.identifier.startpage104
dc.identifier.endpage106
dc.contributor.firstauthorID3375477


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster